Lisata Therapeutics, Inc.

11/06/2025

Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Read more: https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-reports-third-quarter-2025-financial-results

11/06/2025

Join us today for our 3Q 2025 Financial Results Conference Call at 4:30pm ET. To join, please refer to the dial-in info below:

Participant Toll-Free dial: (800) 715-9871
Participant Toll/Int'l dial: (646) 307-1963
Conference ID: 6375221

Webcast: https://edge.media-server.com/mmc/p/d7yefkch/

11/06/2025

Lisata Therapeutics is proud to announce we have been named 'Overall BioPharma Solution of the Year’ in the 5th Annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough.

This achievement marks the second consecutive year Lisata has been recognized by the BioTech Breakthrough program! This consistent recognition underscores the groundbreaking potential of our CendR Platform® to revolutionize the treatment of advanced solid tumors and other difficult-to-treat diseases.

Hear from David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata:

💬 "Winning the ‘Overall BioPharma Solution of the Year’ award further validates Lisata’s core mission and the groundbreaking potential of our CendR Platform® to revolutionize the treatment of solid tumors and other diseases,” stated David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata. "This recognition belongs to the entire Lisata team and our partners who are dedicated to developing therapies that offer significantly better outcomes for patients.”

Read more: https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-wins-2025-biotech-breakthrough-award-overall

11/04/2025

Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent

Read the press release for details: https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-highlights-positive-preclinical-data

10/30/2025

On Thursday, November 6, we will announce our Third Quarter 2025 Financial Results after the close of trading and will host a conference call at 4:30 p.m. ET.

To participate on the call, please refer to the dial-in information provided below:
Participant Toll-Free dial: (800) 715-9871
Participant Toll/Int'l dial: (646) 307-1963
Conference ID: 6375221

10/28/2025

In case you missed it, preliminary data from the pancreatic cancer cohort of our CENDIFOX trial was presented at the American Association for Cancer Research Special Conference in Cancer Research in Boston last month.

The findings demonstrated that certepetide in combination with FOLFIRINOX was safe and feasible in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma. Among patients who completed protocol-prescribed therapy and underwent resection, results showed a 50% R0 resection rate and 70% pathologic partial response rate, with promising early survival data.

Read more: https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-announces-encouraging-preliminary-results

10/21/2025

Lisata Therapeutics’ preliminary CENDIFOX trial data was recently featured in Cancer Network, highlighting the encouraging results from the pancreatic ductal adenocarcinoma cohort presented at the American Association for Cancer Research (AACR).

The article, written by Assistant Editor, Roman Fabbriacatore, discusses how certepetide in combination for FOLFIRINOX demonstrated safety and feasibility in patients with resectable or borderline resectable PDAC, with promising efficacy signals including a 50% R0 resection rate and 70% pathologic partial response rate among evaluable patients.

Read the full article here: https://www.cancernetwork.com/view/certepetide-folfirinox-displays-encouraging-preliminary-feasibility-in-pdac

The addition of certepetide to a FOLFIRINOX-based regimen was safe in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma.

10/20/2025

Advanced solid tumors present unique treatment challenges due to the dense tumor microenvironment that prevents anti-cancer drugs from effectively reaching tumor cells. The CendR Platform® is designed to overcome this critical barrier through targeted pe*******on technology that enhances drug delivery directly to solid tumors.

Our lead investigational drug, certepetide, selectively targets tumor cells and activates a novel uptake pathway that enhances drug delivery while modifying the tumor microenvironment to make cancers more susceptible to treatment. This innovative approach has the potential to revolutionize treatment for advanced solid tumors, ultimately leading to better patient outcomes.

Learn more: https://www.lisata.com/research-technology/cendr-platform/

10/15/2025

We're honored to announce that Lisata's CendR Platform® has been named a finalist in the Drug Delivery Technology category of the Fierce Innovation Awards: Life Sciences Edition 2025!

This recognition from Fierce Life Sciences Events reflects our commitment to addressing a critical challenge in oncology: enabling therapies to selectively target and pe*****te solid tumors more effectively.

Our lead investigational drug, certepetide, is designed to convert the tumor stroma from a barrier into a conduit for drug delivery while modifying the tumor microenvironment. This mechanism is supported by recent preliminary Phase 2b (ASCEND) trial data: patients receiving two doses of certepetide plus standard-of-care achieved 60.8% six-month progression-free survival compared to 25% in the placebo-treated group. These encouraging results further underscore the value of continuing the expedited investigation of certepetide for metastatic pancreatic cancer and other advanced solid tumors.

Winners will be announced on November 19th.

10/13/2025

Lisata Therapeutics to Present at LD Micro Main Event XIX

Read the press release for details: https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-present-ld-micro-main-event-xix

10/08/2025

Lisata is proud to collaborate with Catalent to evaluate certepetide and its analogs for use as SMARTag® payloads across multiple ADCs designed to address difficult-to-treat-diseases.

“This collaboration is based on positive preclinical results generated by Catalent’s use of an iRGD peptide as part of its SMARTag® ADC platform. It underscores our mutual belief in certepetide’s broad potential and is another significant step forward in Lisata’s mission to bring transformative therapies to patients. Catalent’s technology and innovative approach are a perfect complement to certepetide’s biology.” - Kristen K. Buck MD, Executive Vice President of Research and Development and Chief Medical Officer of Lisata

Read the press release for details: https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-and-catalent-announce-global-antibody-drug

Today, Catalent announced with Lisata Therapeutics, Inc., Inc. a new, global license agreement for developing antibody-drug conjugates (ADCs) with the goal of creating a new class of bioconjugate therapies and ultimately improving cancer treatment outcomes.

This collaboration enables Catalent to leverage our proprietary SMARTag® technology platform to incorporate Lisata’s certepetide and its analogs into next-generation ADCs.

We’re proud to work together with Lisata to advance innovation in targeted therapeutics and expand treatment outcomes for patients worldwide.

🔗 Read the full press release here: https://ow.ly/ikPU50X8Fta

09/29/2025

Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial

Read the press release for details: https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-announces-encouraging-preliminary-results